Keros Therapeutics, Inc. KROS
11.62
0.07
0.61%
as of 25 Sep
- Market cap
- $229.0M
- P/E
- 0.0×
Follow KROS
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (17.16%) | (16.79%) | 19.90% | 10.43% |
+8 more TTM periods Free account |
|
| (15.92%) | (15.53%) | 18.24% | 9.75% | ||
ROIC |
(1,345.30%) | (1,668.70%) | 268.69% | 269.50% | |
Return on Tangible Assets |
(32.18%) | (30.22%) | 29.07% | 9.21% | |
Average Days of Receivables |
0.00 | 29.15 | 8.70 | 5.17 | |
Free Cash Flow per Share |
(2.45) | (2.97) | 2.85 | 2.14 | |
Free Cash Flow |
(48.49) | (58.25) | 105.95 | 87.08 | |
Capital Expenditures |
(0.49) | (1.06) | (1.55) | (1.71) | |
Piotroski F-Score |
— | 2.00 | 5.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
(9.23%) | (10.09%) | 18.20% | 6.36% | |
Accounts Receivable Turnover |
0.00 | 3.33 | 57.03 | 127.17 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.05) | (0.04) | |
Research and Development Expense of Revenue |
0.00% | 292.42% | 53.12% | 63.78% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 140.13% | 19.20% | 18.55% | |
Share Based Compensation of Revenue |
0.00% | 78.45% | 11.76% | 12.40% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.58 | 0.67 | 1.24 | 1.38 | |
Depreciation/Fixed assets |
0.43 | 0.40 | 0.35 | 0.32 | |
Capex/Depreciation |
(0.31) | (0.68) | (1.03) | (1.18) | |
Revenue per Share |
0.00 | 1.69 | 6.56 | 6.07 | |
Operating CF per Share |
(2.42) | (2.91) | 2.89 | 2.19 | |
Capex per Share |
(0.02) | (0.05) | (0.04) | (0.04) | |
Capex to Sales |
0.00 | 0.03 | 0.01 | 0.01 | |
Net Profit Margin |
0.00% | (256.60%) | 35.65% | 26.12% |
Columns are period end dates